Shares of Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) traded down 10.6% during mid-day trading on Wednesday . The company traded as low as $2.11 and last traded at $2.20. 105,552 shares were traded during mid-day trading, a decline of 96% from the average session volume of 2,797,964 shares. The stock had previously closed at $2.46.
Chromocell Therapeutics Trading Down 10.6 %
The business’s fifty day simple moving average is $1.01 and its 200 day simple moving average is $0.89.
About Chromocell Therapeutics
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Recommended Stories
- Five stocks we like better than Chromocell Therapeutics
- How to Calculate Options Profits
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Energy and Oil Stocks Explained
- 3 Steel Stocks Soaring After Tariff Announcements
- Where Do I Find 52-Week Highs and Lows?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
